Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10314733 | 1.00 | CA2 (0.44) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL4402227 | 1.00 | CA2 (0.44) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL31370603 | 0.88 | CA2 (0.42) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL7154999 | 0.86 | CA2 (0.50) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL18817541 | 0.86 | CA2 (0.50) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL11190794 | 0.86 | CA2 (0.41) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL22841212 | 0.84 | CA2 (0.40) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL10810001 | 0.84 | CA2 (0.40) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL31362250 | 0.84 | CA2 (0.40) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL935836 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250249131-A1 | SACCHARIDE-BASED MULTI-ARM POLYMERS FOR MEDICAL APPLICATIONS AND HYDROGELS FORMED FROM SAME | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-08-07 | — | — | US | disclosed |
| US-20240316206-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-09-26 | — | — | US | disclosed |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-25 | — | — | US | disclosed |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-25 | — | — | US | disclosed |
| US-20240150298-A1 | ANTIBACTERIAL COMPOUNDS | BLACKSMITH MEDICINES, INC. | 2024-05-09 | — | — | US | disclosed |
| US-20240148875-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-05-09 | — | — | US | disclosed |
| US-20240100166-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-03-28 | — | — | US | disclosed |
| EP-4294792-A1 | ANTIBACTERIAL COMPOUNDS | Blacksmith Medicines, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-117279898-A | Antibacterial compounds | 布莱克史密斯医药公司 | 2023-12-22 | — | — | CN | disclosed |
| US-11786598-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-10-17 | — | — | US | disclosed |
| WO-2011000107-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011000107-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011000106-A1 | IMPROVED CATIONIC LIPIDS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| CN-101080408-A | Trycyclic heterocycles, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2007-11-28 | — | — | CN | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
| CN-1069633-C | Iodo-substituted X-ray contrast agents | NYCOMED IMAGING AS (NO) | 2001-08-15 | — | — | CN | disclosed |
| CN-1166826-A | Iodo-substituted X-ray contrast agents | NYCOMED IMAGING AS (NO) | 1997-12-03 | — | — | CN | disclosed |
| US-4882402-A | Side chain liquid crystalline polymeric media exhibiting third order nonlinear optical response | HOECHST CELANESE CORPORATION (US) | 1989-11-21 | — | — | US | disclosed |
| EP-0260127-A2 | Xanthine derivatives, their preparation and pharmaceutical compositions containing them | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1988-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100166-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | CA2 3725/4885ALDH1A1 2161/4885NPSR1 2165/4885 |
| US-20240148875-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | CA2 3725/4885ALDH1A1 2161/4885NPSR1 2165/4885 |
| US-20250249131-A1 | SACCHARIDE-BASED MULTI-ARM POLYMERS FOR MEDICAL APPLICATIONS AND HYDROGELS FORMED FROM SAME | CD44, ALG1, CSGALNACT1 | CA2 2570/4885ALDH1A1 733/4885NPSR1 2973/4885 |
| US-20240316206-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | CA2 3725/4885ALDH1A1 2161/4885NPSR1 2165/4885 |
| US-20240150298-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, MPO, RPN2 | CA2 4443/4885ALDH1A1 4166/4885NPSR1 4240/4885 |
| US-11786598-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | CA2 3625/4885ALDH1A1 1878/4885NPSR1 2451/4885 |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | CA2 3100/4885ALDH1A1 3257/4885NPSR1 4065/4885 |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | CA2 3625/4885ALDH1A1 1878/4885NPSR1 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.